Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors
Program
Contacts

Actavis terminates the deal with Bioton

31.01.2013

Actavis Group has terminated its joint-venture agreement with Bioton that was supposed to market Bioton’s insulin in the EU, US and Japan, The Warsaw Voice reported.

The termination of the deal is a result of Actavis being taken over by Watson Pharmaceuticals.

Bioton will seek another partner for marketing insulin on those markets, Bioton said.

Source: pharmvestnik.ru


Back to the list





Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34